<?xml version="1.0"?><rdf:RDF xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:edm="http://www.europeana.eu/schemas/edm/" xmlns:wgs84_pos="http://www.w3.org/2003/01/geo/wgs84_pos" xmlns:foaf="http://xmlns.com/foaf/0.1/" xmlns:rdaGr2="http://rdvocab.info/ElementsGr2" xmlns:oai="http://www.openarchives.org/OAI/2.0/" xmlns:owl="http://www.w3.org/2002/07/owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:ore="http://www.openarchives.org/ore/terms/" xmlns:skos="http://www.w3.org/2004/02/skos/core#" xmlns:dcterms="http://purl.org/dc/terms/"><edm:WebResource rdf:about="http://www.dlib.si/stream/URN:NBN:SI:doc-JXZQ1MPK/ab983b0c-cf52-4c64-ae1f-263570a7d432/PDF"><dcterms:extent>1710 KB</dcterms:extent></edm:WebResource><edm:WebResource rdf:about="http://www.dlib.si/stream/URN:NBN:SI:doc-JXZQ1MPK/d64f211f-d32c-4b26-923a-62004e58fe85/TEXT"><dcterms:extent>42 KB</dcterms:extent></edm:WebResource><edm:TimeSpan rdf:about="2005-2025"><edm:begin xml:lang="en">2005</edm:begin><edm:end xml:lang="en">2025</edm:end></edm:TimeSpan><edm:ProvidedCHO rdf:about="URN:NBN:SI:doc-JXZQ1MPK"><dcterms:isPartOf rdf:resource="https://www.dlib.si/details/URN:NBN:SI:spr-8ER5ZBJN" /><dcterms:issued>2024</dcterms:issued><dc:creator>Klemenc, Nejc</dc:creator><dc:creator>Zorec, Barbara</dc:creator><dc:creator>Zvonar Pobirk, Alenka</dc:creator><dc:format xml:lang="sl">številka:1</dc:format><dc:format xml:lang="sl">letnik:75</dc:format><dc:format xml:lang="sl">str. 43-54</dc:format><dc:identifier>ISSN:0014-8229</dc:identifier><dc:identifier>COBISSID_HOST:196360195</dc:identifier><dc:identifier>URN:URN:NBN:SI:doc-JXZQ1MPK</dc:identifier><dc:language>sl</dc:language><dc:publisher xml:lang="sl">Slovensko farmacevtsko društvo</dc:publisher><dcterms:isPartOf xml:lang="sl">Farmacevtski vestnik</dcterms:isPartOf><dc:subject xml:lang="en">critical material attributes</dc:subject><dc:subject xml:lang="en">critical process parameters</dc:subject><dc:subject xml:lang="en">critical quality attributes</dc:subject><dc:subject xml:lang="sl">Dostavni sistemi</dc:subject><dc:subject xml:lang="sl">kritične lastnosti vhodnih materialov</dc:subject><dc:subject xml:lang="sl">kritični atributi kakovosti</dc:subject><dc:subject xml:lang="sl">kritični procesni parametri</dc:subject><dc:subject xml:lang="en">liposomes</dc:subject><dc:subject xml:lang="sl">liposomi</dc:subject><dc:subject xml:lang="en">quality by design</dc:subject><dc:subject xml:lang="sl">vgrajena kakovost</dc:subject><dcterms:temporal rdf:resource="2005-2025" /><dc:title xml:lang="sl">Razvoj dostavnih sistemov na osnovi liposomov z vgrajeno kakovostjo| Development of liposomal delivery systems by quality by design approach|</dc:title><dc:description xml:lang="sl">With the increasing intensity of research and development in the field of liposomes as delivery systems, reflected in numerous regulatory approved products, the broad applicability of these systems is evident. however, due to the complex nature of liposomal formulations, it is crucial to approach the development of such pharmaceutical products thoughtfully. An effective strategy for managing this complexity is the quality by design (QbD) approach, which focuses on understanding the formulation, process and product based on scientific evidence, while effectively managing potential risks. To identify critical factors and optimize both formulations and processes, a systematic and planned approach to experimental design is crucial. This approach includes input variables (materials, processes, expeimental design) and considers the key quality characteristics of liposomal formulations. Such a development approach enables us to integrate quality into the product and provide patients with a high quality, safe and effective advanced drug delivery system</dc:description><dc:description xml:lang="sl">Z naraščajočo intenzivnostjo raziskav in razvoja na področju liposomov kot dostavnih sistemov, ki se odraža v številnih s strani regulativnih organov odobrenih izdelkih, se nazorno kaže tudi široka uporabnost teh sistemov. Zaradi kompleksne narave liposomskih formulacij pa je zelo pomembno, da premišljeno pristopamo k razvoju tovrstnih farmacevtskih izdelkov. Kot močna strategija za obvladovanje te kompleksnosti se pojavlja pristop vgrajene kakovosti (QbD), ki poudarja, da sta za nadzor kakovosti ključna tako razumevanje formulacije, procesa in izdelka na osnovi znanstvenih dognanj kot sočasno učinkovito obvladovanje morebitnih tveganj. Za identifikacijo kritičnih dejavnikov in optimizacijo tako formulacij kot procesov je ključen sistematičen in načrtovan pristop k načrtovanju eksperimentov, ki vključuje vhodne spremenljivke (materiali, procesi, načrtovanje eksperimentov) in upošteva ključne atribute kakovosti liposomskih formulacij. Takšen pristop k razvoju nam omogoča, da kakovost vgradimo v izdelek, bolnikom pa nudimo kakovosten, varen in učinkovit napredni dostavni sistem</dc:description><edm:type>TEXT</edm:type><dc:type xml:lang="sl">znanstveno časopisje</dc:type><dc:type xml:lang="en">journals</dc:type><dc:type rdf:resource="http://www.wikidata.org/entity/Q361785" /></edm:ProvidedCHO><ore:Aggregation rdf:about="http://www.dlib.si/?URN=URN:NBN:SI:doc-JXZQ1MPK"><edm:aggregatedCHO rdf:resource="URN:NBN:SI:doc-JXZQ1MPK" /><edm:isShownBy rdf:resource="http://www.dlib.si/stream/URN:NBN:SI:doc-JXZQ1MPK/ab983b0c-cf52-4c64-ae1f-263570a7d432/PDF" /><edm:rights rdf:resource="http://rightsstatements.org/vocab/InC/1.0/" /><edm:provider>Slovenian National E-content Aggregator</edm:provider><edm:intermediateProvider xml:lang="en">National and University Library of Slovenia</edm:intermediateProvider><edm:dataProvider xml:lang="sl">Slovensko farmacevtsko društvo</edm:dataProvider><edm:object rdf:resource="http://www.dlib.si/streamdb/URN:NBN:SI:doc-JXZQ1MPK/maxi/edm" /><edm:isShownAt rdf:resource="http://www.dlib.si/details/URN:NBN:SI:doc-JXZQ1MPK" /></ore:Aggregation></rdf:RDF>